Scailyte AG, a Luzern, Switzerland-based developer of single-cell technologies, raised CHF 2.75M in seed funding.
Backers included Swisscom Ventures and Zürcher Kantonalbank and existing shareholders. In conjunction with the funding, Dominique Megret, Head of Swisscom Ventures, will join the Board of Directors of Scailyte, along with Pascal Winnen, CEO of Hemex AG.
The company intends to use the funds to enhance the market entry and to speed up further development of ScaiVision, allowing it to be more accessible and attractive to a wider range of customers.
Founded in in June 2017 and led by Peter Nestorov, CEO, Scailyte develops artificial intelligence (AI) based software for analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. The software for biomedical research, commercialized under the brand ScaiVision, will be launched in the beginning of 2019.
The company also offers biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
It is currently in negotiations with leading blue-chip companies for biomarker discovery as a service and has started its first clinical study.